1.64

16.44% 0.24

After Hours: 1.64

Protalix BioTherapeutics Inc. (PLX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Protalix BioTherapeutics Inc. stock is traded at $1.64, with a volume of 1.71M. It is up +16.44% in the last 24 hours and up +49.55% over the past month. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.

Previous Close:

$1.40

Open:

$1.42

24h Volume:

1.71M

Relative Volume:

8.03

Market Cap:

$123.55M

Revenue:

$63.63M

Net Income/Loss:

$10.62M

P/E Ratio:

82.00

EPS:

0.02

Net Cash Flow:

$-8.64M

1W Performance:

+35.84%

1M Performance:

+49.55%

6M Performance:

+42.99%

1Y Performance:

+16.44%

1-Day Range:

$1.40

$1.72

1-Week Range:

$1.20

$1.72

52-Week Range:

$0.8214

$1.90

Protalix BioTherapeutics Inc. Stock (PLX) Company Profile

Name

Protalix BioTherapeutics Inc.

Sector

Healthcare (1205)

Industry

Biotechnology (682)

Phone

972 4 988 9488

Address

2 Snunit Street, Science Park PO Box 455, Karmiel

Employee

190

Twitter

@Protalix_Bio

Next Earnings Date

2024-11-04

Latest SEC Filings

PLX's Discussions on Twitter

Compare PLX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLX	1.63	123.55M	63.63M	10.62M	-8.64M	0.02
VRTX	467.12	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.38	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.35	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.83	24.08B	3.30B	-501.07M	1.03B	11.54

Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy
Apr-17-17	Reiterated	Rodman & Renshaw	Buy
Apr-04-16	Initiated	Rodman & Renshaw	Buy
Apr-23-15	Upgrade	Jefferies	Hold → Buy
Nov-12-14	Reiterated	R. F. Lafferty	Buy
Jan-24-14	Initiated	R. F. Lafferty	Buy
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold
May-02-12	Reiterated	Oppenheimer	Outperform
Apr-30-12	Downgrade	Auriga	Buy → Hold
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy
Nov-09-10	Reiterated	Oppenheimer	Outperform
Oct-14-10	Reiterated	UBS	Buy
Dec-02-09	Reiterated	Hapoalim	Outperform
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform
Dec-01-08	Reiterated	Oppenheimer	Outperform
Mar-11-08	Initiated	UBS	Buy
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform

View All

Protalix BioTherapeutics Inc. Stock (PLX) Latest News

Nov 15, 2024

PLX: Self-Sustaining Rise to Lead in Renal Rare Disease - Yahoo Finance

Nov 15, 2024

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Protalix: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024